Evolus, Inc. — Major Shareholding Notification 2023

Oct 18, 2023

SC 13G/A 1 medytox-sc13ga_101623.htm AMENDMENT TO FORM SC 13G

Field: Rule-Page

Field: /Rule-Page

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)*

Evolus, Inc.

(Name of Issuer)

Common stock, par value $0.00001 per share

(Title of Class of Securities)

30052C107

(CUSIP Number)

October 16, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

• The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1; Options: NewSection

Field: /Page

CUSIP No. 30052C107 Schedule 13G Page 2 of 5

| 1 | NAME
OF REPORTING PERSON I.R.S.
IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Medytox
Inc. | |
| --- | --- | --- |
| 2 | CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
☐ (b) ☐ | |
| 3 | SEC USE ONLY 13g | |
| 4 | CITIZENSHIP
OR PLACE OF ORGANIZATION Republic of Korea | |
| NUMBER
OF SHARES BENEFICIALLY OWNED
BY EACH REPORTING PERSON WITH: | 5 | SOLE
VOTING POWER 3,381,326 |
| | 6 | SHARED
VOTING POWER 0 |
| | 7 | SOLE
DISPOSITIVE POWER 3,381,326 |
| | 8 | SHARED
DISPOSITIVE POWER 0 |
| 9 | AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,381,326 | |
| 10 | CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ | |
| 11 | PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.9% (1) | |
| 12 | TYPE
OF REPORTING PERSON CO | |

(1) Based on a total of 56,971,563 shares of Common Stock outstanding as of July 28, 2023, as reported in the Issuer’s Quarterly Report Form 10-Q filed on August 2, 2023.

Field: Page; Sequence: 2

Field: /Page

CUSIP No. 30052C107 Schedule 13G Page 3 of 5

| Item
1(a) . |
| --- |
| Evolus,
Inc., a Delaware corporation (the “Issuer”) |

| Item
1(b) . |
| --- |
| 520
Newport Center Drive, Suite 1200 |
| Newport
Beach, CA 92660 |

| Item
2(a) . |
| --- |
| Medytox
Inc. |

| Items
2(b) . |
| --- |
| Medytox
Inc. |
| 78
Gangni 1-gil Ochang-eup |
| Cheongwon-gu
Cheongju-si |
| Chungcheongbuk-do
28126 |
| Republic
of Korea |

| Items
2(c) . |
| --- |
| Medytox
Inc. is a company organized under the laws of the Republic of Korea. |

| Item
2(d) . |
| --- |
| Common
stock, par value $0.00001 per share |

Item 2(e) . CUSIP NUMBER: 30052C107

| Item
3 . |
| --- |
| Not
Applicable. |

Item 4 . Ownership.

(a) Amount beneficially owned: Medytox Inc. - 3,381,326

(b) Percent of Class: 5.9%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote: 3,381,326

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 3,381,326

(iv) Shared power to dispose or to direct the disposition of: 0

| Item
5 . |
| --- |
| Not
applicable. |

Field: Page; Sequence: 3

Field: /Page

CUSIP No. 30052C107 Schedule 13G Page 4 of 5

| Item
6 . |
| --- |
| Not
applicable. |

| Item
7 . |
| --- |
| Not
applicable |

| Item
8 . |
| --- |
| Not
applicable. |

| Item
9 . |
| --- |
| Not
applicable. |

| Item
10 . |
| --- |
| By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired
and not held in connection with or as a participant in any transaction having that purpose or effect, other than in connection with a
nomination under §240.14a-11. |

Field: Page; Sequence: 4

Field: /Page

CUSIP No. 30052C107 Schedule 13G Page 5 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: October 18, 2023

| MEDYTOX
INC. | |
| --- | --- |
| By: | /s/
Hyunho Jung |
| Name: | Hyunho
Jung |
| Title: | Chief
Executive Officer |

Field: Page; Sequence: 5

Field: /Page